spacer
home > ict > autumn 2016 > does size really matter?
PUBLICATIONS
International Clinical Trials

Does Size Really Matter?

Over the past few years, outsourcing clinical trials has become an attractive option for sponsored pharmaceutical research. Therapeutic expertise, resource management, technological advantages and cost cutting are some of the primary reasons for any biopharmaceutical sponsor to outsource clinical trials. This has led to tremendous growth in the size and number of CROs in the past two decades. Most of them position themselves as a fullservice CRO in the drug development market, although – based on study-specific requirements – the majority of them are ready to sub-source for their functional needs.

Collaborating with a CRO is now an essential and significant step for sponsors during the clinical development process. The dynamic shift in outsourcing methodology and service fragmentation has left them with critical decisions to be taken at the juncture of CRO sourcing. There are variable sizes of companies on both the sponsor and the CRO side, and the principle of ‘one size fits all’ is not pragmatic from an operability perspective.

Different Options


Full-service and functional outsourcing remain as two distinct but basic models of collaboration. Traditionally, per-study outsourcing has been followed until recently, when strategic partnerships between Big Pharma and sizeable CROs began gaining popularity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mohamed El Malt, MD, PhD, is Chief Medical Consultant at Europital. In addition to 15 years of working as a general and oncology surgeon, Mohamed has more than 32 years of experience as a medical doctor, 18 of which he spent in clinical research and drug development at academic medical centres, as well as in pharma companies and CROs as an investigator, project leader and medical director.
spacer
Mohamed El Malt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement